drugset
drugset / Trial / NCT00189735

A Study to Evaluate FK778 in Kidney Transplant Patients

NCT00189735 ↗

Phase 2 Completed 364 enrolled Astellas Pharma Inc Astellas Pharma Europe B.V. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

A dose finding study to evaluate the safety and effectiveness of FK778 in kidney transplant patients

Timeline

Start
2003-09
Primary completion
2005-10
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MANITIMUS Small molecule — —

Indications

No indication recorded.